Identification of Ovarian Cancer Plasma Biomarkers
卵巢癌血浆生物标志物的鉴定
基本信息
- 批准号:8759302
- 负责人:
- 金额:$ 44.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesBenignBiologicalBiological AssayBiological MarkersBloodBlood TestsCA-125 AntigenCancer BiologyCancer PatientCause of DeathCell LineClear CellClinicalClinical ManagementComplementDiagnosisDiseaseEarly DiagnosisEnzyme-Linked Immunosorbent AssayEpithelial ovarian cancerEvaluationExhibitsFDA approvedFutureGoalsGrantHealthHematopoietic NeoplasmsHumanImageImmunohistochemistryImmunoprecipitationIndividualLabelLaboratoriesMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMalignant neoplasm of ovaryMass Spectrum AnalysisMethodsMolecular WeightMucinousMucinous NeoplasmMusNormal tissue morphologyOutcomeOvarian Mucinous AdenocarcinomaOvarian Mucinous TumorPathologyPatientsPeptide antibodiesPerformancePlasmaPreclinical TestingPredictive ValueProgress ReportsProteinsProteomeProteomicsSamplingSensitivity and SpecificitySerousSerumSiteStable Isotope LabelingStagingSystemTestingTimeTissuesTumor SubtypeTumor TissueUnited StatesValidationWFDC2 geneWomanWorkXenograft procedurebasecohortcostexpectationimprovedin vivoinsightmouse modelmultiple reaction monitoringnovelovarian neoplasmpre-clinicalpublic health relevancestable isotopetumor
项目摘要
DESCRIPTION (provided by applicant): There is an urgent need for new blood biomarkers for epithelial ovarian cancer (EOC), which is the most lethal gynecological cancer in the United States. CA125 is the most commonly used FDA approved biomarker for EOC, but it is not approved for early diagnosis due to inadequate sensitivity and specificity. Furthermore, although CA125 is commonly used to assist in clinical management of the disease after diagnosis, it cannot be used for the substantial portion of EOC patients where CA125 is not substantially elevated at time of diagnosis, which includes the clear cell and mucinous subtypes. Our long-term goal is to identify novel EOC blood-based and tumor tissue biomarkers and conduct laboratory-scale validation to determine which biomarkers can improve early diagnosis and/or clinical management of this disease. Our overall working hypothesis is that the most specific EOC blood biomarkers will be proteins shed by the ovarian tumor into the blood and that are at very low abundance levels in the blood of cancer-free individuals. During the past grant year, we achieved all goals of the original proposal. Specifically, we identified 29 low-abundance, novel biomarkers using a novel in-depth proteome analysis method to identify human proteins in serum or plasma of xenografted mice containing human tumors. These proteins were then shown to be elevated in blood from EOC patients compared with non-cancer controls using a label-free multiplexed multiple reaction monitoring (MRM) mass spectrometry (MS) assay. We have now narrowed this list to 12 high priority biomarkers using biological and functional criteria Our specific goal for the next grant period is to conduct laboratory-scale validation of these 12 biomarkers in several larger patient cohorts to identify the best biomarkers for early diagnosis of
EOC and for improved clinical management of this disease. We will also conduct preliminary evaluations of the capacities of these biomarkers to distinguish among major EOC subtypes, as these are genetically different diseases. To determine whether some biomarkers could complement CA125, we will conduct a focused evaluation of secretomes of clear cell and mucinous ovarian tumors. We will also separately evaluate the predictive value of our biomarkers in the subset of patient plasma samples that exhibit low CA125 levels in our new larger patient cohorts. The two aims that will be pursued over a 5- year period are: 1) Develop tissue and high-throughput preclinical plasma assays for our 12 novel EOC biomarkers, and 2) Validate sensitivity and specificity of our 12 novel EOC biomarker levels in plasma or serum from multiple independent patient cohorts. The biomarkers will be quantified in patient and control plasma or serum using a novel ImmunoMRM method that multiplexes pull-down of targeted intact proteins by commercially-available antibodies using stable isotope-labeled intact proteins as internal standards. It is expected that the subset of our 12 biomarkers that are shown to be useful for early diagnosis and/or clinical management of EOC will advance to larger-scale multi-center, preclinical testing in CLIA certified laboratories in the future.
描述(申请人提供):上皮性卵巢癌(EOC)是美国最致命的妇科癌症,急需新的血液生物标志物。CA125是FDA批准的最常用的卵巢癌生物标志物,但由于敏感性和特异性不足,未被批准用于早期诊断。此外,尽管CA125通常用于辅助诊断后的疾病的临床治疗,但它不能用于大部分卵巢癌患者,因为在诊断时CA125没有显著升高,包括透明细胞和粘液亚型。我们的长期目标是确定新的基于EOC血液和肿瘤组织的生物标记物,并进行实验室规模的验证,以确定哪些生物标记物可以改善这种疾病的早期诊断和/或临床治疗。我们的总体工作假设是,最具特异性的EOC血液生物标志物将是卵巢肿瘤进入血液的蛋白质,这些蛋白质在未患癌症的人的血液中处于非常低的丰度水平。在过去的拨款年度内,我们达到了原来建议的所有目标。具体地说,我们使用一种新的深入蛋白质组分析方法确定了29个低丰度的新生物标记物,以识别含人类肿瘤的异种移植小鼠血清或血浆中的人类蛋白。然后,通过无标记多重反应监测(MRM)质谱仪(MS)分析显示,与非癌症对照组相比,卵巢癌患者血液中的这些蛋白质水平升高。我们现在已经使用生物学和功能标准将这一列表缩小到12个高优先级生物标记物。我们下一个资助期的具体目标是在几个更大的患者队列中对这12个生物标记物进行实验室规模的验证,以确定最好的生物标记物用于早期诊断。
EoC和改善这种疾病的临床治疗。我们亦会初步评估这些生物标志物区分主要的EoC亚型的能力,因为这些亚型在遗传上是不同的疾病。为了确定某些生物标志物是否可以补充CA125,我们将对透明细胞和粘液性卵巢肿瘤的分泌体进行重点评估。我们还将单独评估我们的生物标记物在我们新的更大的患者队列中表现出低CA125水平的患者血浆样本子集中的预测价值。将在5年内实现的两个目标是:1)为我们的12个新的EOC生物标记物开发组织和高通量临床前血浆分析;2)验证我们的12个新的EOC生物标记物水平在多个独立患者队列的血浆或血清中的敏感性和特异性。生物标志物将在患者和对照血浆或血清中使用一种新的免疫核磁共振方法进行量化,该方法使用稳定的同位素标记的完整蛋白作为内部标准,通过商业上可获得的抗体对目标完整蛋白的下拉进行多路复用。预计我们的12个生物标志物中被证明对EOC的早期诊断和/或临床管理有用的子集将在未来在CLIA认证的实验室中推进到更大规模的多中心临床前测试。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID W. SPEICHER其他文献
DAVID W. SPEICHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID W. SPEICHER', 18)}}的其他基金
Purchase of a Q Exactive HF mass spectrometer system for metabolomics
购买用于代谢组学的 Q Exactive HF 质谱仪系统
- 批准号:
9274622 - 财政年份:2017
- 资助金额:
$ 44.07万 - 项目类别:
Identification of ovarian cancer plasma biomarkers
卵巢癌血浆生物标志物的鉴定
- 批准号:
7736151 - 财政年份:2009
- 资助金额:
$ 44.07万 - 项目类别:
Identification of ovarian cancer plasma biomarkers
卵巢癌血浆生物标志物的鉴定
- 批准号:
8192927 - 财政年份:2009
- 资助金额:
$ 44.07万 - 项目类别:
Identification of ovarian cancer plasma biomarkers
卵巢癌血浆生物标志物的鉴定
- 批准号:
8296102 - 财政年份:2009
- 资助金额:
$ 44.07万 - 项目类别:
Protein Modification with Oxidative Stress in ALI
ALI 中氧化应激的蛋白质修饰
- 批准号:
7796691 - 财政年份:2009
- 资助金额:
$ 44.07万 - 项目类别:
Identification of ovarian cancer plasma biomarkers
卵巢癌血浆生物标志物的鉴定
- 批准号:
7881494 - 财政年份:2009
- 资助金额:
$ 44.07万 - 项目类别:
Identification of Ovarian Cancer Plasma Biomarkers
卵巢癌血浆生物标志物的鉴定
- 批准号:
8910661 - 财政年份:2009
- 资助金额:
$ 44.07万 - 项目类别:
Discovery and validation of novel serological biomarkers of colon cancer
结肠癌新型血清学生物标志物的发现和验证
- 批准号:
7212781 - 财政年份:2006
- 资助金额:
$ 44.07万 - 项目类别:
相似海外基金
Genome analysis-based prediction model development for response to stereotactic radiosurgery in benign brain tumors
基于基因组分析的预测模型开发,用于良性脑肿瘤立体定向放射外科治疗的反应
- 批准号:
23K08495 - 财政年份:2023
- 资助金额:
$ 44.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
- 批准号:
10719777 - 财政年份:2023
- 资助金额:
$ 44.07万 - 项目类别:
Environmentally Benign Precise Transformations of Alkenes by Chiral Chalcogenide Catalysts
手性硫属化物催化剂对环境无害的烯烃精确转化
- 批准号:
22KJ2498 - 财政年份:2023
- 资助金额:
$ 44.07万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Learners to LeAders in benign Urology, benign Nephrology, and non-Cancer Hematology
良性泌尿外科、良性肾脏病学和非癌症血液学领域的学习者和领导者
- 批准号:
10726042 - 财政年份:2023
- 资助金额:
$ 44.07万 - 项目类别:
The role of estrogen receptor alpha in prostatic fibrosis contributing to benign prostatic hyperplasia
雌激素受体α在导致良性前列腺增生的前列腺纤维化中的作用
- 批准号:
10607151 - 财政年份:2023
- 资助金额:
$ 44.07万 - 项目类别:
Development of a medical device to resolve benign esophageal stricture by heating and traction
开发通过加热和牵引解决良性食管狭窄的医疗设备
- 批准号:
23H03765 - 财政年份:2023
- 资助金额:
$ 44.07万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of benign/malignant differentiation method for thyroid follicular tumor using organoids
利用类器官开发甲状腺滤泡性肿瘤良恶性鉴别方法
- 批准号:
23K08075 - 财政年份:2023
- 资助金额:
$ 44.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis
p53在散发性肿瘤发生良性向恶性转变中的参与和作用机制
- 批准号:
10720034 - 财政年份:2023
- 资助金额:
$ 44.07万 - 项目类别:
I-Corps: Mitigating Multidrug Resistant Bacterial Infections with Biocompatible and Environmentally Benign Nanoantibiotics
I-Corps:利用生物相容性且对环境无害的纳米抗生素减轻多重耐药细菌感染
- 批准号:
2306943 - 财政年份:2023
- 资助金额:
$ 44.07万 - 项目类别:
Standard Grant
Identifying the role of the gut microbiome in the etiology of benign breast disease
确定肠道微生物组在良性乳腺疾病病因学中的作用
- 批准号:
10359959 - 财政年份:2022
- 资助金额:
$ 44.07万 - 项目类别:














{{item.name}}会员




